Xenon Pharmaceuticals (NASDAQ:XENE) Insider Christopher John Kenney Sells 1,410 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 1,410 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the sale, the insider directly owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher John Kenney also recently made the following trade(s):

• On Tuesday, March 10th, Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total value of $166,564.81.

Xenon Pharmaceuticals Trading Down 4.6%

Shares of NASDAQ XENE opened at $55.23 on Friday. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95. The stock has a 50 day moving average of $43.71 and a two-hundred day moving average of $41.92. The stock has a market cap of $4.59 billion, a P/E ratio of -12.67 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter last year, the business earned ($0.84) earnings per share. As a group, research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new stake in Xenon Pharmaceuticals in the 4th quarter valued at approximately $33,000. Blue Trust Inc. raised its stake in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares in the last quarter. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at approximately $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at approximately $39,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on XENE shares. Bank of America reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday. Wedbush upped their target price on shares of Xenon Pharmaceuticals from $47.00 to $64.00 and gave the company an “outperform” rating in a report on Tuesday. Guggenheim reiterated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, Wells Fargo & Company boosted their price target on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $71.94.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.